Clinical meaning
Androgen Insensitivity Syndrome arises from loss-of-function mutations in the androgen receptor (AR) gene, located on the long arm of the X chromosome at Xq11-12. The AR gene spans over 90 kb and contains 8 exons encoding a 919-amino acid nuclear receptor protein. The AR protein belongs to the nuclear receptor superfamily and contains four functional domains: the N-terminal transactivation domain (NTD, exon 1), the DNA-binding domain (DBD, exons 2-3) containing two zinc finger motifs that bind androgen response elements (AREs) in target gene promoters, the hinge region (exon 4) containing the nuclear localization signal, and the C-terminal ligand-binding domain (LBD, exons 4-8) that binds testosterone and DHT. Over 1,000 distinct AR mutations have been catalogued in the Androgen Receptor Gene Mutations Database. These mutations can be classified by their functional consequence: complete loss of ligand binding (LBD missense mutations disrupting the hydrophobic ligand-binding pocket), impaired DNA binding (DBD mutations affecting zinc finger coordination or ARE recognition), defective nuclear translocation (hinge region mutations), and impaired coactivator recruitment (mutations affecting the AF-1 and AF-2 transactivation surfaces that interact with p160 coactivators such as SRC-1, SRC-2/TIF2, and SRC-3). In CAIS, the AR is completely non-functional, whereas in PAIS, residual receptor activity ranges from minimal to substantial, explaining the clinical spectrum. The molecular mechanism of normal androgen signaling involves testosterone diffusing into the cell and either binding directly to the AR or being converted to the more potent DHT by 5-alpha reductase type 2 in genital skin. Upon ligand binding, the AR undergoes conformational change, dissociates from heat shock proteins (HSP90, HSP70), homodimerizes, and translocates to the nucleus where it binds AREs and recruits the transcriptional machinery to activate androgen-responsive genes. In AIS, this signaling cascade is disrupted at various points depending on the specific mutation. The testosterone-to-estrogen conversion pathway remains intact: aromatase (CYP19A1) in peripheral tissues converts testosterone to estradiol, which acts through functional estrogen receptors to drive breast development and fat distribution. The hypothalamic-pituitary-gonadal axis is affected because testosterone cannot exert negative feedback on GnRH and LH secretion through the dysfunctional AR, resulting in elevated LH, elevated testosterone, and elevated estradiol levels. The ratio of testosterone to DHT and the absolute testosterone level can help distinguish AIS from 5-alpha reductase deficiency, another important cause of 46,XY DSD.